Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic PIK3CA mutant solid tumor types Meeting Abstract

  

Authors:	Jhaveri, K. L.; Bedard, P. L.; Cejalvo, J. M.; Hart, L. L.; Juric, D.; Kelly, K.; Lockhart, A. C.; Melnyk, A.; Moore, K. N.; Nemunaitis, J. J.; Oliveira, M.; Patel, M. R.; Sachdev, J.; Smith, D.; VanderWalde, A.; Ware, J. A.; Jin, H.; Wilson, T. R.; Wei, M. C.; Baselga, J.
Abstract Title:	Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic PIK3CA mutant solid tumor types
Meeting Title:	52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	34
Issue:	15 Suppl.
Meeting Dates:	2016 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2016-05-20
Start Page:	616s
Language:	English
ACCESSION:	WOS:000404712500624
DOI:	10.1200/JCO.2016.34.15_suppl.TPS11621
PROVIDER:	wos
Notes:	Meeting Abstract: TPS11621 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/154973